Evolent Health Reports Massive Goodwill Impairment, 26.6% Revenue Drop, and Widened Net Loss to $579.4M in Annual Report

summarizeSummary

Evolent Health's 2025 annual report details a $398.0 million goodwill impairment, a 26.6% revenue decline, and a net loss of $579.4 million, alongside increased debt and a DOJ investigation, signaling severe financial challenges.

check_boxKey Events

• Massive Goodwill Impairment

  The company recorded a $398.0 million non-cash goodwill impairment charge for the year ended December 31, 2025, a direct result of a prolonged decline in its Class A common stock price (from $23.35 to $6.67 between Oct 2024 and Oct 2025). This charge significantly impacted operating expenses and net loss.

• Significant Revenue Decline

  Total revenue decreased by $678.5 million, or 26.6%, to $1.88 billion for 2025, primarily due to contractual updates with Performance Suite customers, including a customer transition and narrowing of scope for others.

• Dramatically Widened Net Loss

  Net loss attributable to common shareholders increased substantially to $579.4 million in 2025, compared to a net loss of $93.5 million in 2024, driven largely by the goodwill impairment and higher interest expenses.

• Increased Long-Term Debt

  Long-term debt, net, nearly doubled to $970.5 million as of December 31, 2025, up from $490.5 million in 2024, following the issuance of $166.8 million in 2031 Convertible Senior Notes and the conversion of Series A Preferred Stock into a $175.0 million Second Lien Term Loan Facility.

auto_awesomeAnalysis

Evolent Health's annual report reveals a deeply concerning financial picture, confirming and elaborating on the significant challenges previously hinted at in the recent 8-K filing. The most striking event is the $398.0 million goodwill impairment charge, which represents over 100% of the company's current market capitalization. This impairment was directly triggered by a prolonged decline in the stock price, indicating a substantial re-evaluation of the value of past acquisitions and future prospects. The company also reported a significant 26.6% decrease in revenue to $1.88 billion and a dramatically widened net loss to $579.4 million for 2025, compared to $93.5 million in 2024. This revenue decline is attributed to contractual changes with major customers, including transitions and scope narrowing. Furthermore, long-term debt nearly doubled to $970.5 million, increasing the company's leverage. The disclosure of a Civil Investigative Demand from the Department of Justice regarding a False Claims Act investigation adds a material legal and reputational risk. While management states they have sufficient liquidity for the next twelve months, the overall financial deterioration, coupled with regulatory uncertainties from the 'One Big Beautiful Bill Act' and heavy customer concentration, presents a highly negative outlook for investors.